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ABSTRACT 
Introduction 
Studies report that up to 75 percent of cancer survivors experience cognitive difficulties during cancer 
treatment or at the cancer survivorship stage. These difficulties impact work and productivity, social 
participation, and other areas of daily life. 
Purpose 
This dissertation contains a literature review that aims to present a summary of the current literature 
surrounding cancer-related cognitive change (CRCC), and a systematic review. Objectives of the 
systematic review were to identify and categorise interventions trialled to manage CRCC, and make a 
judgement on the impact of these interventions.  
Study methods 
This study was a systematic review with meta-analysis. A search of six databases was completed, 
including years 2007-2017 and limited to randomised control trials (RCTs) published in English. A 
preliminary meta-analysis was attempted using Comprehensive Meta-Analysis software. 
Study results 
A total of 23 studies were identified that presented interventions for CRCC and met selection criteria. 
Interventions fell into three categories: cognitive training based intervention, cognitive behaviour 
therapy (CBT), and alternative/complementary therapies. Overall, CBT interventions had no 
significant impact on cognitive functioning, while the other categories significant improvement in 
cognitive performance. 
Conclusions 
Current research into intervention options for the management of CRCC is still limited in scope. 
Alternative and complementary therapies seem to be effective and accessible to cancer survivors. CBT 
was not found to be an effective CRCC intervention. The findings are significant for clinical decision 
making by practitioners recommending interventions for CRCC. There is need for further, high-quality 
research in this area that addresses the broader population of cancer survivors. 
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Current methods in cancer-related cognitive change intervention: 
A systematic review with meta-analysis. 
 
SECTION 1: LITERATURE REVIEW 
 
Introduction 
With the lifelong impacts of a cancer diagnosis, it is extremely important for cancer survivors to 
understand treatment options, possible side-effects, and long-term rehabilitation. One common side 
effect that is rarely discussed, or even recognised by medical practitioners, is cancer-related cognitive 
change (CRCC) (Dong, Crone, & Wise, 2014). CRCC refers to changes in cognitive capacities that are 
directly linked to cancer or its treatment, and that often last for years after treatment has been 
completed (Dong, Crone, & Wise, 2014). It is often colloquially referred to as “chemobrain”. In order 
to effectively address and treat this dysfunction, it is essential to understand what it is and how it 
effects the lives of those experiencing it. More importantly, it is necessary to understand what 
interventions are available to survivors and which of these interventions have been shown to be 
effective. Therefore, this study aims to collate the interventions used to treat CRCC from the available 
literature, a Boolean search of six databases was conducted. Within this search, key terms “cancer” 
OR “neoplasm” AND “cognition” OR “cognitive” OR “neurocognitive” OR “chemo brain” OR 
“chemo fog” were used to identify pertinent articles. Searches were limited to the last 10 years to 
ensure that all information was relevant and up-to-date. This literature review will discuss current 
research in the area of CRCC, including its prevalence, impacts on functionality, causes, assessment of 
cognitive impairment, and current treatment options.  
Current cancer prevalence and treatment 
Within the global population, the prevalence of cancer is currently rising, and is expected to continue 
to rise in coming years. This is partially due to population growth and the ageing population, but is 
also related to an increase in behaviours and lifestyle factors that are known to increase the risk of 
cancer (Torre, et al., 2015). A 2017 report by the World Health Organisation advises that over the next 
two decades, the number of new cases of cancer are expected to increase by approximately 70% 
(World Health Organisation, 2017). This rise in cancer prevalence subsequently means that a greater 
number of individuals will be diagnosed with cancer, and undergo a cancer treatment at some stage of 
their lives. However, more effective medical technologies and research also means that cancer survival 
rates have been steadily increasing since 1984 (Connell, Rompotis, Martin, Bartlett, & Harvey, 2017). 
Some of the most common systemic cancer treatments currently used to manage cancer include 
chemotherapy, radiation therapy, and surgical treatment. Each of these treatments aims to remove or 
kill cancerous cells in the body and can be associated with a range of side effects (Shapiro & Recht, 
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2001). Consequently, the presence of long-term side effects of cancer and cancer treatments are 
becoming more apparent, including CRCC (Correa & Ahles, 2008). A study on patient perceptions of 
chemotherapy side-effects has shown that psychosocial complaints related to social activity, work, and 
home duties are among some of the most commonly reported issues faced by chemotherapy patients 
(Nadege, et al., 2002).  
When examining cancer and cancer-related issues, there is a notable publication bias in which cancers 
that have relatively low mortality rates, or are more common than others, are often over-represented in 
the literature. Examination of the search results demonstrated this pattern clearly. Chen, et al. (2014) 
reports that one of the most common cancers that affects women worldwide is breast cancer. The 
authors then goes on to state that the survival time for women experiencing this is relatively long, in 
comparison to other prevalent cancers. Further, survival issues that relate to cancer, such as cognitive 
changes, are also focused on breast cancer populations. For instance, results from a nationwide survey 
in the US stated that “the extant literature on cognitive dysfunction is limited regarding associations 
with demographic and clinical characteristics outside of research with breast cancer survivors” 
(Schmidt, et al., 2016, p. 305). This suggests that the large majority of information regarding cancer 
treatments, side effects, and related cognitive impairment is exclusive to the breast cancer population. 
It is therefore essential to consider whether the results of such research are generalisable to the broader 
population of cancer survivors.  
What is cancer-related cognitive change? 
Cognitive performance is defined by the Occupational Performance Model of Australia as “the 
operations and interactions of mental processes used during task performance” (Ranka & Chapparo, 
1997, p. 59). Within this, the domains that are commonly used to classify neurocognitive disorders 
include language, learning and memory, social cognition, complex attention, executive function, and 
perceptual-motor function (Sachdev, et al., 2014). Accordingly, the CRCC can be defined as a change 
in cognitive performance that impacts everyday functioning and falls into any of the above categories. 
However, within the literature, the definition of CRCC is rarely this definitive, and is often 
inconsistent (Shilling, Jenkins, & Trapala, 2006). A universal definition of the condition is notably 
lacking (Kanaskie, 2012). Player, et al. (2014, p. 230) defines chemo-brain as “subtle, yet persistent 
mild mental dysfunctions”. Meanwhile Aurgyriou, et al. (2011, p. 127) states the definition to be 
“impairment of patients’ memory, learning, executive function, attention, and visuospatial skills 
during and after chemotherapy”. A 2007 review of the literature found that 45 percent of included 
studies on cognitive functioning associated with chemotherapy did not contain an explicit definition of 
cognitive impairment (Vardy, Rourke, & Tannock, 2007). Each of these studies, however, agree that 
cognitive changes are often subtle and therefore difficult to detect and examine (Player, Mackenzie, 
Willis, & Loh, 2014; Argyriou, Assimakopoulos, Iconomou, Kalofonos, & Giannakopoulou, 2011; 
Vardy, Rourke, & Tannock, 2007). Variation in how the condition presents between individuals, may 
also contribute to difficulties in developing a definition. 
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Although the precise definition is not clear, a review of current literature provides a relatively strong 
portrayal of what CRCC is with regard to its impact on cognitive function. Hess and Insel (2007) 
conducted a review of the literature around chemotherapy-related change in cognitive function, 
including a meta-analysis, and found that verbal and visual memory, executive function, and motor 
function show significant decline in cancer patients after treatment. This is supported by Miao et al. 
(2016) who stated that common areas in which cognitive impairment is reported are memory, 
attention, and executive function, all of which significantly affect quality of life. A qualitative study of 
breast cancer survivors completed in 2012, found that half the participants reported deficits in short-
term memory such as forgetting appointments and misplacing items (Myers, 2012). However, in a 
2015 study of learning and memory performance in breast cancer patients, it was found that attention 
span was significantly decreased, while there was no significant change in delayed memory or 
inaccurate memory factors as measured by the California Verbal Learning Test-II (CVLT-II), despite 
participants reporting forgetfulness. This suggested that difficulties in memory as reported by breast 
cancer survivors may stem from attentional dysfunction (Root, et al., 2015). A similar study was also 
published in 2015 examining memory performance in breast cancer survivors post-treatment, which 
also used the CVLT-II to examine cognitive function. This study, again, found no significant 
impairment in the delayed recall factor of the assessment, however found evidence to suggest that 
forgetfulness as experienced by cancer survivors is not the result of impaired memory, but rather an 
inability to accurately encode information into working memory (Root, Andreotti, Tsu, Elmore, & 
Ahles, 2016). 
Aside from the previously mentioned study, a number of others provide evidence for attention deficit 
in cancer patients and survivors. Chen, et al. (2014) used the attention network test (ANT) to examine 
the attentional abilities of breast cancer patients treated with chemotherapy. Results of the study 
showed that participants treated with chemotherapy demonstrated impairment in each of the three 
attention networks: alerting, orienting, and executive control (Chen, et al., 2014). A more recent 
examination considered whether concentration problems, as reported by cancer survivors, can also be 
objectively measured by the sustained-attention-to-task response and found that abnormal patterns of 
sustained attention could be detected in this population when compared to a healthy control. This 
particular study was unique in its consideration of mind-wandering and distractibility in breast cancer 
survivors, particularly discussing possible content of thoughts during mind-wandering. It concluded 
that these experiences, as described by the participants, were consistent with objective measures of 
attention (Kam, et al., 2016).  
Unlike memory and attention, detecting impairment in executive function is made more difficult 
because it encompasses several processes, including problem solving, reasoning, and planning (Miao, 
et al., 2016). In a recent study, the Stroop Interference Test was used as a measure of executive 
functioning as it measures the information processing speed of the individual as well as attention 
skills. This same study concluded that there is evidence for an association between chemotherapy and 
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executive function impairment (Miao, et al., 2016). This research supported findings of a previous 
study published in 2011 examining brain activation and executive function in breast cancer patients 
with a range of treatment backgrounds. The results of the study found that more perseverative errors 
and reduced processing speed were present in the breast cancer group when compared with the healthy 
control (Kesler, Kent, & O’Hara, 2011). This is further supporting evidence for the relationship 
between cancer and impaired executive function.  
Prevalence of CRCC 
Current literature presents various research evidence for the prevalence of CRCC within the global 
population of cancer survivors. As CRCC is not clearly defined, and has varying presentations, there is 
some disagreement in the reported prevalence of the condition. However, studies suggest that up to 
75% of cancer patients will experience cognitive impairment at some stage during systemic cancer 
treatment, while a further 35% experience continuation of this in the months and years after 
completion (Janelsins, et al., 2011; Kayl, Wefel, & Meyers, 2006). In 2010, a large sample (3108 
participants) of cancer survivors within the United States were involved in a study of cancer 
survivorship known as the LIVESTRONG survey (Schmidt, et al., 2016). An examination of 
perceived cognitive dysfunction reported that 47.5% of the individuals that participated in this survey 
described experiences of cognitive dysfunction (Schmidt, et al., 2016). This study included a variety of 
cancer types, however it is important to note that the highest prevalence of CRCC was reported among 
those with central nervous system tumours. Cognitive function was also prevalent in participants 
diagnosed with breast cancer, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, colorectal cancer, 
testicular cancer, prostate cancer, and various other cancers. These findings are therefore important as 
previous literature on CRCC prevalence is saturated with breast cancer populations (Schmidt, et al., 
2016). Despite the significant number of studies reporting high prevalence of CRCC in cancer 
survivors, there is still some controversy as to whether the condition exists.  
In contrast to the previously discussed literature, a some studies reported that no change could be 
detected in the cognitive capacities of cancer survivors (Mehlsen, Pedersen, Jensen, & Zachariae, 
2009; Jenkins, et al., 2006; Debess, Riis, Engebjerg, & Ewertz, 2010). For example, Mehlsen, et al. 
(2009) examined 36 cancer patients undergoing chemotherapy, and 17 healthy control participants, 
using a range of neuropsychological assessments, and found no significant differences in cognitive 
performance between the two groups. Notably, this study tested participants prior to starting 
chemotherapy, and 4-6 weeks after the completion of chemotherapy. Having only one assessment 
time, aside from the pre-treatment assessment, may impact the ability of the results to reflect 
incremental changes, or changes that may have occurred during the treatment process and resolved 
prior to the final assessment. The timing of assessment also does not account for long-term or delayed-
onset cognitive changes that may have occurred. A previous study by Jenkins, et al. (2006) found 
similar results to that completed by Mehlsen et al., however took a long-term approach, assessing 
participants at baseline (pre-chemotherapy), 6 months, and 18 months. This study used a prospective 
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method to examine neuropsychological performance in 85 breast cancer patients, and 49 healthy 
control subjects and concluded that the majority of subjects demonstrated no cognitive impairment 
over the course of chemotherapy or after its completion, with no significant differences recorded from 
the healthy control group. 
Despite this evidence, Andreotti, et al. (2016) proposes a possible reason for the underestimation of 
cognitive impairment within studies. After assessment of the test-retest reliability of tests comprising a 
standard neurocognitive battery, as well as overarching cognitive domains, this study suggests that 
many of the standardised assessments used to objectively measure cognitive impairment are limited in 
detecting subtle changes, particularly when the baseline cognitive performance of participants is 
average to above average. Although these standardised measures are likely to be reliable for more 
pronounced cognitive dysfunction and disorders, CRCC, as described previously, is generally subtle 
and therefore current tests are not sensitive enough for this population (Andreotti, et al., 2016). This, 
however, refers specifically to the objective measurement of cognitive function and does not address 
the reliability of self-report measures of cognitive function and patient-perceived impairment. The 
significant variation between subjective and objective reports of CRCC is another important factor 
impacting how CRCC prevalence is reported.  
There are conflicting reports in current literature regarding the relationship between perceived 
cognitive impairment and objective cognitive impairment as measured by neuropsychological tests.  A 
2012 systematic review of literature relating to the two measurement methods found that perceived 
cognitive impairment is reported at higher levels than is detected in neurological tests. The study also 
found that there is often minimal to no relationship between the two measurement approaches 
(Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 2012). In direct contrast with these results, 
Von Ah and Tallman (2014) found high correlation between perceived cognitive impairment and 
perceived cognitive ability measures on the Functional Assessment of Cancer Therapy-Cognitive 
Scale (FACT-Cog), and various objective cognitive performance measures of memory and executive 
function. A number of studies have suggested possible reasons for discrepancies between subjective 
and objective measures of cognitive function, such as the use of static scores over measures of 
cognitive change, or deficits in meta-memory, however none of these studies fully account for the 
inconsistencies observed between objective and subjective measures of cognitive impairment 
(O'Farrell, Smith, & Collins, 2017; Collins, Paquet, Dominelli, White, & MacKenzie, 2017).  
Impacts of CRCC on daily life 
More important than the prevalence of CRCC, is the way in which it influences the daily lives of those 
who experience it. The impact of CRCC on individuals varies widely depending on their roles and 
routines, as well as the areas of cognition that are impaired and the level to which these impairments 
occur. Overall, patients experiencing CRCC commonly report poorer quality of life and difficulty 
functioning in everyday tasks, notably in work, social participation, and home lives (Boykoff, Moieni, 
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& Subramanian, 2009). Player et al. (2014) presents a qualitative study of the experiences of women 
living with breast cancer-related cognitive changes. After interviewing nine women, the paper reported 
the key concerns of the participants were around employment and independence in daily living 
activities, such as domestic tasks.   
Several papers have examined the impact of CRCC on employment and work outcomes (Boykoff, 
Moieni, & Subramanian, 2009; Calvio, Peugeot, Bruns, Todd, & Feuerstein, 2010; Selamat, Loh, 
Mackenzie, & Vardy, 2014). Calvio, et al. (2010) conducted a study examining cognitive performance 
and work limitations of 235 participants including 112 breast cancer survivors, and 112 non-cancer 
control group participants. This study found that the cancer survivors experienced significantly higher 
levels of job stress and work-related memory difficulties than healthy controls. Further, it reports a 
relationship between work output and survivors’ own ratings of cognitive limitations. Overall, results 
of this study suggest that impaired cognitive functioning, in particular perceived cognitive impairment, 
is related to decreased job performance and work output. In line with these findings, Boykoff et al. 
(2009) found that the difficulty of relatively simple tasks in the workplace was increased by impaired 
attention and reduced memory performance. Consequently, the time taken to complete such tasks is 
increased and work output is decreased. For other survivors, cognitive impairment has also been found 
to impact confidence in returning to work, and applying for jobs (Selamat, Loh, Mackenzie, & Vardy, 
2014). Further, survivors often report feeling as though they require more effort at work to perform 
tasks that were not previously difficult, and to maintain attention and productivity in the workplace 
(Selamat, Loh, Mackenzie, & Vardy, 2014). 
As well as productivity at work, many survivors also find they experience decreased productivity at 
home. A 2014 meta-analysis of qualitative studies regarding quality of life in breast cancer survivors 
with cognitive impairment found that survivors who considered themselves to be homemakers had 
issues maintaining this role, often due to difficulties with attention and memory. The same study 
suggests that the ability of these women to function within their homemaker roles is also impacted by 
decreased self-confidence and lowered expectations of their own abilities (Selamat, Loh, Mackenzie, 
& Vardy, 2014). However, it has also been found that some women report minimal impact on their 
home-lives as they work harder to compensate for cognitive difficulties. Although these women 
reported finding tasks at home more difficult, they did not feel they had been slowed down at home, 
due to their increased efforts (Von Ah, Habermann, Carpenter, & Schneider, 2013). 
Another commonly reported impact of cognitive change in cancer survivors is the influence it can 
have on social participation and relationships. Selamat et al. (2013) reported that feelings of 
embarrassment and lowered self-esteem negatively influence interactions with family and friends, and 
affect participation in social activity. Further, a qualitative study including interviews with 22 breast 
cancer survivors was published in 2013 and reported substantial social impacts of cognitive 
impairment in approximately 60% of participants. A number of the participants in this study described 
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memory impairments as a major contributing factor to discomfort in social situations, often forgetting 
simple things such as names and dates (Von Ah, Habermann, Carpenter, & Schneider, 2013). Many of 
the social tensions reported in this study are also related to a lack of understanding of the condition by 
friends and family. Many of these women discussed occasions in which friends and family did not 
understand that difficulties with memory or attention were related to cognitive impairment (Von Ah, 
Habermann, Carpenter, & Schneider, 2013). 
Within each of the previously mentioned impacts of CRCC, there are also underlying psychological 
and psychosocial issues to be considered. Wu, et al. (2012) previously found that confidence and self-
efficacy are significantly impacted by perceived cognitive impairment and that this, in turn, has 
negative impacts on mental well-being. Further, it has also been reported that breast cancer survivors 
experiencing CRCC often feel misunderstood and consequently feel isolated during, or after, treatment 
(Von Ah, Habermann, Carpenter, & Schneider, 2013). As mentioned above, Selamat et al. (2013) also 
described lowered self-esteem as experienced by breast cancer survivors, while a lack of self-
confidence and self-perceptions of cognitive difficulties can notably increase anxiety and stress for 
individuals looking for work (Boykoff, Moieni, & Subramanian, 2009). 
Causes of CRCC 
The causes of CRCC are highly debated and mostly unknown. Several causes have been proposed in 
the literature, while the mechanism behind these changes remains largely unknown (Bower, 2008). 
While confounding factors, such as fatigue and depression, and systemic cancer treatment are 
commonly suggested as causes of CRCC, impairment has also been detected in survivors prior to 
undergoing any treatment. A 2010 study examining 10 newly diagnosed breast cancer survivors, as 
well as 9 healthy controls used functional magnetic resonance imaging (fMRI) during a selective 
attention and working memory task to examine whether alterations had occurred in brain function pre-
chemotherapy. The results of the study determined that the breast cancer survivors showed diminished 
cognitive functioning when compared with the healthy control participants, before undergoing 
chemotherapy (Cimprich, et al., 2010). Similarly, Berman et al. (2014) also used fMRI to examine 
neurocognitive response prior to systemic treatment and found that pre-treatment cognitive 
impairment did occur. This study further examined the relationship between self-reported worry and 
cognitive dysfunction, between which a significant correlation was found. (Berman, et al., 2014) 
There is also evidence for systemic cancer treatment as a cause for cognitive dysfunction. Cruzado et 
al. (2014) observed cognitive function in colon cancer patients prior to, and after, chemotherapy, using 
a neuropsychological battery of tests. This study supported those previously mentioned in finding that 
37% of participants demonstrated cognitive impairment pre-chemotherapy, however also detected 
significant cognitive decline in 56% of participants post-chemotherapy. Alternatively, Noad et al. 
(2004) used a retrospective design to compare cognition in participants who had undergone 
radiotherapy and surgery for the treatment of pituitary tumours, with those who had undergone only 
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surgery. Data from this study found that those treated with radiotherapy did have significantly greater 
difficulty with cognitive tests than those who had not been exposed to radiotherapy. However, it was 
also found that cognitive function in both treatment groups was lower than the normal population. 
Overall, these papers suggest that systemic cancer treatment adds to the cognitive impacts of the 
disease itself (Cruzado, et al., 2014; Noad, Narayanan, Howlett, Lincoln, & Page, 2004). 
Aside from cancer and cancer treatment, other cancer side-effects and psychological issues have been 
hypothesised as factors influencing cognitive dysfunction. Results from the previously discussed 
LIVESTRONG survey, demonstrate a strong association between depression at the time of survey and 
the odds of reporting perceived cognitive dysfunction (Schmidt, et al., 2016). Meanwhile, other studies 
have also reported evidence for depressive symptoms exacerbating cognitive dysfunction (Danhauer, 
Legault, Bandos, Kidwell, & Costantino, 2013; Vearncombe, et al., 2009). Vearncombe et al. (2009) 
suggests that vulnerability of survivors to cognitive difficulties may be increased by psychological 
issues, while Danhauer et al. (2013) also describes an association between depressive symptoms and 
memory. Fatigue and symptoms of post-traumatic stress disorder (PTSD) are some of the other 
confounding factors discussed in the literature. A recent Chinese study assessed 204 breast cancer 
survivors and made use of hierarchical linear regression to understand the relationships between PTSD 
symptoms, fatigue, and depression. This paper concluded that fatigue and PTSD symptoms are key 
risk factors for self-reported cognitive dysfunction (Li, Yu, Long, Li, & Cao, 2015).  
Assessment of CRCC 
In order to gain a better understanding of the causes of CRCC, but also to understand its impact and 
develop effective intervention, it is essential to accurately identify and assess cognitive change. 
However, the assessment of cognition can be difficult for several reasons. Due to the unpredictable 
nature of cancer diagnoses, and the rapid treatment initiation process, cancer survivors rarely undergo 
cognitive testing prior to receiving systemic treatment. This lack of baseline data therefore makes 
assessment of cognitive change difficult (Asher & Myers, 2015). Further, as previously discussed, 
cognitive dysfunction has also been known to occur in cancer survivors pre-treatment. For this reason, 
even in those who do have cognitive testing prior to treatment may not reflect the full cognitive 
change that has occurred in comparison to their normal function (Asher & Myers, 2015). This 
considered, a number of assessment tools have been trialled and are commonly used to detect CRCC. 
Vardy et al. (2006) compared three screening instruments used to detect cognitive impairment in a 
sample of 31 cancer patients. These tools were the High Sensitivity Cognitive Screen (HSCS), the 
Headminder and Coghealth, and the FACT-Cog. As expected, there was no correlation between self-
report and objective measures. It was also found that the HSCS demonstrated significant practice 
effect and therefore is not ideal for repeat testing within short timeframes. The authors suggest that 
Headminder and Coghealth may be more useful than the standard neuropsychological testing that is 
often used (Vardy, et al., 2006). Further, a 2013 review of CRCC assessment strategies presents 
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guidelines for choosing the appropriate neuropsychological test depending on the domain of cognition 
and characteristics of the test. This review identified almost 80 objective tests that may comprise a 
neuropsychological battery, as well as 8 self-report measures. It should be noted, however, that this is 
not a systematic review and therefore is not necessarily a comprehensive review of all literature 
available at the time. Overall, it concluded that many standardized tests are not suited to clinical use 
due to accessibility and interpretation difficulties, while subjective tests provide better insight into 
functional considerations (Jansen, 2013). 
Treatment of CRCC 
A number of studies have been completed trialling various interventions for cancer-related cognitive 
change. These include cognitive rehabilitation, physical interventions, complementary and alternative 
medicines, and pharmacological approaches. When examining and assessing interventions for CRCC, 
it is also essential to consider the accessibility of these treatments including the costs and time 
constraints involved. Also important is accessibility to treatment for individuals in rural and remote 
areas. 
In relation to cognitive rehabilitation and training, Damholdt et al. (2016) examined the viability of a 
web-based cognitive training program on a sample of 157 breast cancer survivors. The randomised 
control trial found that this intervention did not influence perceived cognitive impairment, however 
significant improvements were observed in both a test of working memory, and verbal learning. An 
earlier study by Ferguson, et al (2012), also used a randomised control trial approach to assess 
Memory Attention Adaption Training (MAAT) in breast cancer survivors. This was a smaller trial, 
however completed assessments at a greater number of time points, over a longer period, up to 2 
months post-intervention. The MAAT intervention used cognitive behavioural therapy where 
participants attend sessions in person and learn to apply a range of strategies to common situations of 
daily life. Results of this trial found that the intervention improved performance in verbal memory and 
had high participant satisfaction. Unlike the former study, however, this was a relatively small trial 
with a sample size of only 40 (Ferguson, et al., 2012).  
Aside from direct cognitive interventions, there is also evidence for a relationship between physical 
activity and cognition in the cancer survivor population both in the short term, and over a period of 
two years (Marinac, et al., 2015; Husson, Mols, Ezendam, Schep, & van de Poll-Franse, 2015).  A 
study of neuropsychological test results in 136 breast cancer survivors has previously shown a strong 
association between moderate-to-vigorous physical activity and the cognitive domain of information 
processing, while light physical activity showed no association (Marinac, et al., 2015). Consequently, 
physical activity has been used as a target for cognitive intervention. Zimmer et al. (2016) presents a 
systematic review of exercise interventions used to treat CRCC and found that some physical 
movement programs, such as yoga, were effective in decreasing cognitive dysfunction. However, it 
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was also concluded that the overall quality of these studies was insufficient and that further research is 
needed in the area. 
Various complementary and alternative medicines have also been tested and demonstrated to influence 
cognitive impairment. The National Health and Medical Research Council (NHMRC) of Australia 
describes complementary medicines as “a range of health care medicines, therapies, and other 
products that are not generally considered within the domain of conventional medicine” that are used 
in combination with conventional medicines. They may also be known as alternative medicines when 
used as “an alternative to conventional medicine” (National Health and Medical Research Council, 
2014). For cognitive impairment, these interventions include meditation techniques, mindfulness 
interventions, and herbal medicines (Chan, et al., 2011; Milbury, et al., 2013; Johns, et al., 2016).  
Finally, other studies look at common medications, often requiring prescriptions, to manage the effects 
of CRCC. A 2009 randomised control trial observed the effect of Modafinil, a drug used for increasing 
wakefulness, in a group of breast cancer survivors experiencing cognitive dysfunction (Kohli, et al., 
2009). Although this study aimed to examine fatigue as a primary outcome, the results and 
conclusions primarily discussed memory and attention performance. By targeting fatigue and 
alertness, the results found that the medication significantly improved cognitive performance in the 
participants in the intervention group (Kohli, et al., 2009). Meanwhile, Lawrence et al. (2016) 
presented a randomised trial of Donepezil, commonly used in Alzheimer’s patients, and its effect on 
self-reported cognitive impairment. This intervention included 62 participants and ran for 24 weeks, 
with a battery of neuropsychological tests, as well as subjective measures, being used for assessment. 
Improvement was shown in the intervention group on two memory assessments, however not in any of 
the other assessment tools, including subjective measures (Lawrence, et al., 2016).  
Implications  
Overall, literature surrounding cancer-related cognitive change has been increasing in recent years. 
However, there are still a lot to be discovered about how CRCC can be measured and treated. 
Although studies have been completed that trial interventions for this condition, the quality of these 
studies and size of the effects were not sufficiently discussed. There are a number of reasons that make 
it essential to consider and address this gap in the literature. First, the literature discussed in this 
review presents evidence for interactions between cognitive deficits and various other cancer side-
effects, including fatigue, depression, self-efficacy, and symptoms of PTSD. Therefore, it is logical 
that addressing and managing cognitive concerns may also improve these factors, and overall quality 
of life for cancer survivors (Mandelblatt, Figueiredo, & Cullen, 2003). Further, having a clear 
understanding of the true effect of proposed interventions and the quality of the studies that examine 
them is essential for improving the quality of the interventions. This allows further, high-quality 
research, and the development of new and innovative methods of cognitive intervention for cancer 
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survivors. A synthesis of current literature in this area would provide opportunities to fill gaps in 
CRCC intervention research.  
Conclusion 
In summary, cancer-related cognitive change is a significant issue experienced by up to 75 percent of 
cancer survivors, predominantly surveyed amongst women with breast cancer. This condition has vast 
negative impacts on many areas of everyday life for these individuals, including employment, home 
life, social relationships, and psychological well-being. Currently, the actual causes of CRCC is 
unknown, however there is evidence to suggest that is the result of a combination of the disease itself, 
systemic cancer treatment, and other confounding factors such as depression and fatigue. In general, 
the assessment of CRCC has been found to be difficult due to discrepancies between objective and 
subjective measures, however there is a large range of tools available that may be used in practice. 
Overall, interventions for managing CRCC fall into the categories of cognitive training, physical 
intervention, complementary and alternative medicine, and pharmacological intervention. However, 
the quality of studies that trial these interventions is not well known, and the effectiveness of each of 
these categories in comparison to one another is also unknown. This provides an opportunity for 
further research in the future. 
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ABSTRACT 
Purpose 
Cancer-related cognitive change (CRCC) is a condition that is observed in a large proportion of cancer 
survivors, impacting activities of daily living and overall wellbeing. Objectives of this study were to 
identify and categorise interventions previously trialled to manage CRCC, and to analyse the impact of 
these interventions.  
Methods 
This study was a systematic review with meta-analysis. A search of six databases was completed, 
including years 2007-2017 and limited to randomised control trials (RCTs) published in English. 
Meta-analysis was accomplished using Comprehensive Meta-Analysis software. 
Results 
A total of 23 studies were identified that presented interventions for CRCC and met selection criteria. 
Interventions fell into three categories: cognitive training based intervention, cognitive behaviour 
therapy (CBT), and alternative/complementary therapies. Overall, CBT interventions had no 
significant impact on cognitive functioning, while the other categories significantly improved 
cognitive performance. 
Conclusions 
The findings of this study suggest that current research into intervention options for the management 
of CRCC is limited in scope, however suggests that alternative and complementary therapies are both 
effective and accessible to cancer survivors. Further, based on current research, CBT is not 
recommended as an effective CRCC intervention. 
Implications for Cancer Survivors 
This study provides insight into current options for the management of CRCC, which may improve the 
lives of those who experience it. The findings are significant to inform clinical practice and assist 
practitioners in recommending interventions. Awareness of limitations in the scope of the research, 
and the financial and time burdens associated with interventions will allow practitioners to make 
informed decisions around these recommendations. There is need for further, high-quality research in 
this area that addresses the broader population of cancer survivors.  
 
Key words: neoplasm, cognition, cancer survivorship, chemo-brain, CRCC, intervention 
studies 
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Current methods in cancer-related cognitive change intervention: A 
systematic review with meta-analysis 
INTRODUCTION 
Cancer-related cognitive change (CRCC) is an issue faced by up to 75% of cancer survivors [1, 2]. This refers to 
impairments in cognitive functioning that are the direct result of cancer, or cancer treatment. Currently, the 
definition, assessment, and impact of CRCC is inconsistent within the literature [3]. This may be due to variation 
in how the condition presents within cancer survivors, as well as differences between objective measurement of 
cognition and self-reported cognitive outcomes [4]. This paper therefore uses the Occupational Performance 
Model of Australia (OPMA) definition of cognition to understand CRCC. The OPMA reports cognitive 
performance to be “the operations and interactions of mental processes used during task performance” [5 (p39)]. 
Therefore, cancer-related cognitive change will be considered to be change that occurs in any of these mental 
process, including language, learning and memory, complex attention, and executive function, areas commonly 
used to classify neurocognitive disorders [6]. 
For individuals living with this condition, areas of daily life including self-care, social activity, work, and 
productivity, are often affected [7]. However, the impacts are rarely the same between cases and individuals. 
Previous studies have demonstrated that impaired cognitive functioning can increase job stress, cause anxiety in 
seeking employment [7], and deeply impact job performance and work output [8]. Further, there are significant 
psychosocial impacts in relation to feelings of security in the workplace, and self-efficacy as an employee [7].  It 
has also been reported that feelings of embarrassment and low self-esteem can influence the way in which cancer 
survivors experiencing CRCC participate in social activities and interact within social relationships [9]. 
Developing effective and accessible interventions for CRCC is therefore essential in allowing cancer survivors to 
return to every-day life and providing the best possible quality of life to these individuals. 
A number of interventions have been, or are currently being, trialled for the management and prevention of 
CRCC. These can be grouped into four main areas [10]. i)Cognitive training, or rehabilitation, and interventions 
that involve cognitive behaviour therapy (CBT) may be used with the goal of directly improving a certain area of 
cognition [11]. For example, the use of memory training has been shown to improve memory performance in 
certain cancer populations [12]. ii) The use of exercise and physical activity as a means of reducing the effects of 
CRCC and improving cognition in cancer survivors [13]. As well as directly addressing cognition, physical 
activity interventions have also aimed to improve cancer-related fatigue, with cognitive functioning as a 
secondary outcome [14]. Due to the link between fatigue and cognition, as well as other cancer-related 
symptoms, it is important to consider interventions in which cognition may not be the primary outcome. iii) 
Interventions that include yoga and tai chi are also common within the literature. These fall under meditative, or 
mindfulness, interventions and are most often linked to breast cancer survivors [15]. iv) Medications may be 
used to improve cognition, such as Modafinil and other prescription medications that are used to increase 
alertness or treat Alzheimer’s disease [16, 17]. Within the medication grouping, a number of alternative 
medicines have also been considered, including various herbal medicines.  
Despite the existence of intervention trials for CRCC, the prevention and management of CRCC is not always 
discussed with cancer patients or survivors [18]. Further, there are few services available to cancer survivors that 
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provide management or support for cognitive concerns [19]. What has been lacking, until now, is a 
comprehensive analysis of the cognitive interventions that are available to cancer patients and how effective 
these interventions are. This is important for the construction of an effective cancer rehabilitation program to 
support survivors through short-term, and long-term recovery. Therefore, this study conducted a systematic 
review to identify and categorise the interventions that have been trialled for CRCC in adult populations, and to 
analyse the impact of these interventions. The study will also aim to examine the quality of these studies. 
 
METHODOLOGY 
Study criteria 
This study was a systematic review of randomised control trials (RCTs) that meet the criteria reported below. 
The study protocol is registered with PROSPERO (registration no.CRD42017076868). Studies were excluded if 
they were not RCTs or did not provide a description of the randomisation process. The type or stage of systemic 
medical cancer treatment was not considered in the selection of studies for this review. Studies were not 
excluded based on the type or stage of cancer treatment participants were undergoing at the time of the study.  
Inclusion criteria 
• The RCT studied the effects of an intervention focused on cognitive functioning, not systemic cancer 
treatment. 
• Cognitive function was measured as a primary or secondary outcome. 
• Participants within the RCT were adults (18 years and over) of any gender. 
• Participants within the RCT had a primary cancer diagnosis. 
• Interventions were included that used alternative or complementary medicines accessible by 
participants without the need for a medical prescription. 
Exclusion criteria  
• Cancer diagnosis of participants occurred prior to adulthood. The relationship between cognitive 
function and illness in childhood is vastly different to that of adulthood as the developing brain is 
particularly vulnerable to change [20].  
• Primary diagnosis of participants were cancers of the brain and spinal cord (including head and neck 
cancer). Cancers of this kind are likely to have a direct effect on the brain and therefore cognitive 
functioning will be impacted via a different mechanism to CRCC [21].   
• Study participants had undergone, or were undergoing, treatment that directly targets the brain or spinal 
cord (eg, cranial radiation or chemotherapy directly delivered to the brain or spine).  
• Pharmacological interventions that were medically prescribed and therefore inaccessible to the general 
population of cancer survivors.    
• Studies in languages other than English. 
Outcome measures and interventions 
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Studies included in this review examined cognitive function as a primary or secondary outcome measure. 
Measures included either objective cognitive functioning via valid neuropsychological testing, or subjective self-
reported experiences of participants. Studies that examined quality of life (QoL) were included in the study if 
they provided an analysis of the cognitive domain separately to overall QoL. Interventions were defined as any 
treatment, distinct from systemic cancer treatment, targeted at improving cognitive functioning that did not 
involve the medical prescription of drugs. Herbal medications and over-the-counter medications were therefore 
not excluded from the study.  
Search methods 
An electronic search of six databases was completed in consultation with an academic liaison librarian at the 
University of Sydney to identify relevant articles in the literature published between 2007 and 2017. The date of 
this search was the 22nd May 2017. Due to rapidly improving cancer technologies, and constant changes in 
cancer statistics, early cancer research is quickly becoming outdated and irrelevant. Limiting this search to the 
last 10 years allowed for the most up-to-date interventions and technologies to be included in the study, 
particularly as systematic research regarding CRCC has previously been completed during the mid 1990s to 
early 2000s [19]. Databases included in this search were Medline, CINAHL, AMED, PsychINFO, OTseeker, 
and the Cochrane Database of Systematic Reviews, accessed via the University of Sydney library. Searches were 
limited to the English language and randomised control trials. In databases where restriction by study type was 
not possible, key terms “RCT” and “trial” were added to search terms. Full search strategy can be found in 
appendix II 
Study selection 
Articles identified through the database search were exported to Endnote for screening and removal of 
duplicates. One researcher completed the initial title screen of articles and those deemed relevant were 
transferred to a Microsoft Excel spreadsheet for further screening. Two researchers then independently screened 
abstracts of the remaining articles against the inclusion and exclusion criteria. Disagreements regarding the 
inclusion of studies were resolved via discussion and consensus. Reasons for exclusion were recorded and 
documented in a PRISMA flow chart. Following this, full-text articles were screened independently by two 
researchers using the same method. Remaining articles following this screen were included in the final review.  
Data extraction and quality analysis 
Eligible studies were grouped based on their consideration of cognition as a primary or secondary outcome. 
Studies in which cognition was examined within overall QoL were considered secondary, regardless of whether 
QoL was a primary outcome. Data was then extracted from all studies using an adaption of the Cochrane Data 
Extraction and Assessment Template [22]. Information was extracted regarding the characteristics of the study, 
the intervention being trialled, and the results of the study. Following this, quality assessments were completed 
on each of the studies using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for RCTs (Appendix 
III) and the results recorded. This tool consists of 13 items assessing risk of bias within RCTs on which the 
assessor checked “yes”, “no”, or “unclear”. Completing quality assessment of this kind is essential for assessing 
the strength of any results or conclusions drawn within the studies. A quality score for each of the studies was 
calculated as the percentage of “yes” marks received out of the total applicable items. 
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Data synthesis 
Using the information gathered via the data extraction methods, identified interventions were assessed using a 
tool developed by the researchers (Appendix IV). This tool assessed interventions based on the level of training 
of those administering the intervention, intensity, duration, follow up, cognitive measures used, and accessibility 
to cancer survivors. Interventions were categorised into groups based on their characteristics and mean outcome 
scores of both control and intervention groups entered into the Comprehensive Meta-Analysis software for 
analysis of effect size. For RCTs in which assessments were completed at numerous timepoints, mean scores 
were only entered for the final timepoint to demonstrate the overall effect of the intervention at completion of the 
study. Studies were not included in the meta-analysis if they did not provide sufficient data for outcome 
measures, including means and standard deviations at baseline and final timepoints.  
 
RESULTS 
Study selection 
The total number of studies identified via electronic search was 1512, of which 23 studies met the inclusion 
criteria following the screening process (figure 1). Of the 294 studies included in the abstract screen, 15 abstracts 
were found to be sources of disagreement between the researchers. These articles were reviewed and discussed 
to reach consensus. Of the included studies, 16 examined cognition as a primary outcome, while the remaining 
seven included cognitive function as a secondary measure or as an incidental finding of the primary outcome. 
One study was included (Poppelreuter 2008) in the review that examined participants aged 17 years to 65 years. 
Based on the mean age of participants in this study (42.6 years), and the close proximity to the 18-year inclusion 
age for the review, both researchers agreed that the study should be included in analysis despite not meeting age 
criteria. The PRISMA flow diagram (figure 1) outlines the full selection process, including reasons for exclusion 
of studies.  
Study characteristics 
A total of 2797 participants from nine countries were included across the 23 studies. The majority of the research 
(13 studies) was completed in the USA, and middle-aged populations represented a high proportion of 
participants. A single study was completed in Australia. Of the population groups, 14 studies (60.8%) were 
specific to breast cancer patients and survivors, while only one study did not include breast cancer patients as 
participants at all. The remaining studies either looked at a select group of cancers (including breast cancer), or 
were open to all cancer types.  Of the 24 articles, 16 examined participants who had completed primary cancer 
treatment. Finally, 78.2% of included articles has been published in the five years prior to the search (since 2012) 
Full characteristics of each study are presented seen in table 1.  
Intervention characteristics 
Of the 23 included studies, 25 interventions were identified. One study (Freeman 2015) included two 
intervention groups, as well as a waitlist control, while another (May 2009) compared two intervention groups in 
the absence of a no-intervention control. The most common interventions within studies included various forms 
of alternative and complementary therapies (13 studies), cognitive retraining or rehabilitation (six studies), and 
interventions involving cognitive behaviour therapy (four studies). Alternative and complementary therapies 
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were those generally considered to be outside the domain of conventional medicine [23]. Included in this group 
are yoga and Tai Chi based practices, herbal medications, support group, psychosocial, and behavioural 
interventions, mindfulness or meditation based interventions, acupuncture, and speed-feedback therapy (table 1). 
Aside from yoga and tai chi, no physical activity interventions were included in the final study. The majority of 
trials examining physical activity interventions were excluded at the abstract screen stage as they did not meet 
the criteria “addresses cognition as a primary or secondary outcome”. 
Of the interventions in which the level of training of the individual administering the intervention was classified 
as “low” (no specific training in cognition), all five were within the alternative and complementary medicines 
category. These included trained yoga instructors, meditation specialists, and acupuncturists. However, this 
category also scored the highest regarding accessibility of the intervention to the general population, with five of 
the six “high” accessibility scores falling within alternative and complementary therapies. Overall, only two 
studies (Miki 2014, Rottman 2015) obtained “low” accessibility scores (8.7%). The majority of the studies 
(60.8%) obtained “high” scores for duration of intervention (over six weeks in duration), while none scored low 
for this criteria.   
Common outcome measures 
With regards to cognitive measures, nine studies used only self-report measurement tools, while two relied solely 
on neurocognitive testing. The remaining studies examined a combination of the two. Across the 23 studies, 15 
assessment tools were identified for assessing self-reported (perceived) cognitive function. A number of these 
also included numerous subscales or domains. The most commonly used of these were the European 
Organisation for Research and Treatment of Cancer- Quality of Life C30 (EORTCQoL C30), and the Functional 
Assessment of Cancer Therapy- Cognition (FACT-Cog). These tools were used in 30.4% and 34.8% of studies, 
respectively. There was notably more variation in objective measures. Of the 13 studies that included objective 
assessment, 10 used a combination of multiple measures, with the most commonly used objective measurement 
tools used being the trail making test, digit symbol, and the Rey Auditory Verbal Learning Test (RAVLT). 
Studies within the cognitive training based category tended to favour the use of neuropsychological testing. 
Across these six studies, a total of 11 subjective tests were conducted at the final timepoint, compared to 43 
objective tests. CBT based studies used a relatively equal combination of both subjective and objective 
measures, with six tests of each completed across the four studies. Finally, studies within the alternative and 
complementary therapies group was the most likely to use subjective measures alone, with seven of the 13 not 
including any objective measure of cognition. 
Risk of bias within studies 
Within the critical appraisal of the included studies (table II), the highest percentage score was 85% (Johns 
2015), followed by two studies with a score of 83% (Chan 2011, Miki 2014). The lowest score observed was 
46%, occurring in three studies (Oh 2014, Poppelreuter 2008, and Rottman 2015). Overall, the lowest scoring 
items across studies were those regarding concealed allocation and true randomisation of participants (items one 
and two), with only two studies scoring “yes” to the question: was allocation to treatment groups concealed? 
Four items on the checklist had “yes” answers for all 23 studies. These were items regarding analysis of 
participants in their assigned groups, reliability of measurements, and appropriate trial design and statistical 
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analysis (items 9, 11-3). No obvious relationships were observed between critical appraisal scores and study 
results.  
Meta-analysis 
Of the included studies, 17 provided sufficient data to be included in the meta-analysis. Meta-analysis was 
conducted within the three categories of intervention identified above. Results of this analysis demonstrate that, 
overall, CBT interventions did not have a significant effect on cognitive performance across measures (figure II, 
analysis 1.2). Of the four studies included in this category, two had a positive mean effect on cognition 
(Ferguson 2016, Ferguson 2012), while the other two favoured the control group (Goedendorp 2014, May 2008). 
However, none of these results were statistically significant. No heterogeneity was observed in this analysis (I2= 
0%, Q value= 1.93, P value= 0.59). In contrast, both alternative/complementary therapies, and cognitive training 
based interventions in the current pooled studies demonstrated a significant positive impact on cognition (figure 
II; analysis 1.1 & 1.3).  
Between-study heterogeneity in the cognitive training analysis was moderate (I2 = 60.54%, Q value= 7.60, p 
value 0.06). Like CBT, this analysis included four studies, two of which significantly favoured the intervention 
group (Cherrier 2015, Von Ah 2014), while two reported no significant difference between the groups. However, 
meta-analysis found that overall, study results were significantly in favour of the intervention group (figure II; 
analysis 1.1). Finally, meta-analysis of alternative and complementary therapies demonstrated a significant 
positive effect on cognition, with the largest difference in means between treatment groups occurring in Johnston 
2011 (std diff in means= 1.5), patient education integrated with acupuncture. Of the nine studies included in this 
analysis, none favoured the control condition, while five significantly favoured the intervention condition (figure 
II; analysis 1.3). However, this analysis had a considerably higher Q value than other studies of 18.38 (I2= 56.46, 
P value= 0.02). 
Results of studies not included in meta-analysis 
Within the six studies not included in the meta-analysis, four fell into the alternative and complementary 
therapies category (Chan 2013, Derry 2015, Oh 2014 & Rottman 2015), while the remaining two were cognitive 
training based interventions (Ercoli 2015 & Poppelreuter 2008). The results of these studies, as reported by the 
authors, are as follows. Chan 2013, using Chinese Herbal Medicine as an intervention, reported no significant 
improvement in cognition over time, nor in comparison to the placebo control. Derry 2015 found significantly 
lower perceived cognitive impairment at three month follow up in the yoga intervention group compared with 
the control group (mean difference (MD) in BCPT scores 0.31, p value= 0.003). Similarly, Oh 2012 reported 
significant improvements in self-report cognitive function using a medical Qigong intervention compared to 
controls (MD in EORTC 7.78, p value= 0.015; MD in FACT-Cog perceived cognitive impairment 4.70, p 
value= 0.029; MD in FACT-Cog perceived cognitive abilities 3.61, p value= 0.031). Rottman 2012 
demonstrated that, at 6 month follow up, the control group demonstrated greater increases in cognitive 
functioning than the psychosocial rehabilitation group (p value= 0.03), with mean scores of cognitive function 
decreasing in the intervention group at both 1 month and 6 month assessment. Of the studies trialling cognitive 
training and rehabilitation, Ercoli 2015 reported that the intervention group improved significantly over time in 
comparison to the control group on all cognitive measures (p values: Patient’s Assessment of Own Functioning 
Inventory= 0.01, Rey Auditory Verbal Learning test total= 0.02 and delayed recall= 0.007), while Poppelreuter 
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2008 established significant improvement in objective measures of cognition after neuropsychological 
rehabilitation, as well as in the control group.  
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DISCUSSION 
Location of reviewed studies 
Among the 24 studies that were included in this review, only nine countries were represented in the research. 
Although limiting the database searches to English was expected to restrict the scope of the review, this finding 
was not expected. As anticipated, the USA made up a large proportion of the studies, however only one study 
was completed in Australia (Oh 2014).  This trend has also been noted in other systematic reviews looking at 
cognitive function in cancer patients, such as Mishra et al (2012), in which 40% of the 40 included studies were 
completed in the US [45].  Given that 70% of English first-language speakers are within the United States [46], a 
dominance of this country within the English-written publications is not surprising. However, globally, over 75 
territories consider English as a primary language, secondary language, or consider its significance as an 
international language [46]. For this reason, there was expected to wider representation of countries in the 
included studies. The observed pattern may be representative of the global cancer incidence and mortality rates. 
The 2012 GLOBOCAN study for the International Agency for Research on Cancer reported that 20.5 percent of 
global cancer cases occurred in the Americas, while only 1.1 percent occurred in Oceania regions. Further, 15.5 
percent of cancer-related deaths occurred in the Americas, and 0.7 percent in Oceania [47]. High incidence and 
mortality is likely to be a motivating factor for the commission of cancer research in this country. Compared to 
other countries, the US also has a dominance of private investment in health services which may also increase 
investment in various areas of research. Regardless of the reason for this, it is important for practitioners and 
cancer survivors in Australia, and other minimally represented countries, to be aware of differences between 
countries that may limit the generalisability of research from overseas to their own populations when 
recommending interventions for CRCC.  
Absence of exercise interventions  
Noteworthy in this review is the lack of physical exercise interventions that were included in the final analysis 
following the application of inclusion criteria. One study (May 2009), examined a combination of physical 
activity and CBT, however the exercise component of the intervention could not be assessed due to the lack of a 
no-intervention control. Significant evidence has previously been produced supporting a strong relationship 
between physical activity and cognition [48, 49]. Further, Zimmer et al (2016) recently completed a systematic 
review of exercise interventions used in cancer survivors and found that some physical movement programs 
were effective in decreasing cognitive dysfunction [50]. Studies within the review included 6 animal studies and 
3 cross-sectional studies which were not appropriate for inclusion in this systematic review. Three of the other 
studies included in Zimmer et al. (2016) were included in the current review, however were classified as 
alternative therapies, rather than exercise therapies (yoga, Qigong, speed-feedback therapy). While the initial 
search for this review identified several studies trialling exercise-based interventions, none met all of the 
selection criteria. As most exercise based interventions were removed from the study due the absence of a 
cognitive outcome measure, it may be hypothesised that exercise-based interventions target confounding factors, 
such as fatigue and depression, as opposed to cognition directly. For example, Perna et al (2010) demonstrated 
that an exercise intervention decreased clinical depression in breast cancer patients [51], with depression 
previously being linked to decreased cognitive function [52]. Zimmer et al (2016) also supports this in 
suggesting that further research is required in this area that controls for potential confounders, as well as noting 
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that many of the trials on physical activity and cognition are cross-sectional studies or animal studies [50]. A 
wider review may be required to account for interventions that target these confounders or to consider a broader 
range of participants and study-types. 
Quality of research and risk of bias 
The quality of studies included in systematic reviews is important in ensuring that conclusions of such research 
is reliable and accurate. In particular, low quality primary studies can influence the results of meta-analyses by 
exaggerating the overall treatment effect [53]. Quality analysis of the studies included in this review determined 
two areas of concern. These areas were the randomisation of participants to groups, and the concealment of 
allocation. These are two key factors that contribute to selection bias [22]. Considering the low number of 
studies that successfully addressed these items, the overall evidence supporting the interventions they address is 
weakened. In contrast, a previous systematic review of interventions for CRCC found that selection bias was, 
overall, well reported and categorised as low risk of bias [10].  Considering this, and the large number of studies 
scored as “unsure” in these items, it is more likely that the low scores regarding selection bias in this review are 
due to an absence of information regarding randomisation and concealment within the studies, rather than poor 
methodology in these areas. For clinicians, being aware of potential biases in the literature, and the reasons for 
these biases, is likely to influence the recommendation of interventions for individuals experiencing CRCC.  
Of the 24 studies included in this review, only three received scores under 50% for total quality, indicating that 
the research is, in general, relatively reliable. However, no study received positive scores on all items and 
therefore there is still potential for improvement in research quality in the future to provide stronger evidence for 
the identified cognitive interventions.  
Identified categories of CRCC intervention 
The three key categories of cognitive intervention that were identified in this review were cognitive training, 
cognitive behavioural therapy, and alternative/complementary therapy. CBT is a widely used therapy that has 
origins in psychology and is commonly used in mental health settings for disorders such as obsessive-
compulsive disorder and depression [54]. Though this approach has been shown to be effective for psychological 
disorders [55], CBT interventions in this review were not determined to have any significant effect on cognitive 
functioning. However, it should be noted that these interventions made up only a small proportion of the 
included studies (4 studies) and therefore further research is needed to establish a larger evidence base and 
further examine impact on cognitive function.  
The four cognitive training interventions included in the review used various approaches comprised of group and 
individual training and rehabilitation, in-person training, and online training courses. These interventions have 
previously been used in the treatment of Alzheimer’s disease, age-related cognitive decline, and brain injury, and 
commonly target specific domains of cognition, such as memory training and attention training [56]. They also 
commonly include the use of compensatory strategies that aim to maintain functionality in daily life, despite 
subtle cognitive impairment [57]. Findings of the meta-analysis in this study suggest that this is an effective 
method of improving cognition in cancer survivors.  
Finally, the alternative and complementary therapy category encompassed a range of interventions acting as 
substitutes for, or in coordination with, standard therapies. Key inclusions within this category are mind-body 
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interventions (yoga, Tai Chi, Qigong), herbal remedies, and meditation-based interventions. Although the 
usefulness and legitimacy of alternative and complementary therapies is often questioned [58], partially due to 
negative associations with the term “alternative medicine,” this review found that a number of these 
interventions significantly improved cognition. One concern relating to studies is this category is difficulties 
with adherence to, or standardisation of, intervention. As these interventions are often self-managed by 
participants and completed at home, monitoring adherence to the intervention protocol can be difficult [59]. For 
example, several studies trialling yoga interventions demonstrate low adherence to intervention by participants 
[44]. Ben-Erye et al (2014) previously examined cancer survivor adherence to complementary medicines and 
found that 83 of the 160 participants were non-adherent [59]. It also reported the previous use of complementary 
medicines were predictive of adherence. This suggests that clinicians should consider the attitudes and 
experiences of patients with complementary medicines before recommending this approach. 
Characteristics of identified interventions 
In general, the interventions identified in this review were determined to be relatively accessible to the wider 
population in regard to cost and availability, particularly complementary and alternative therapies. However, the 
majority of interventions were also completed in time frames over six weeks, and therefore required a greater 
time commitment from participants. As financial burden can be high for cancer survivors, and CRCC can have a 
negative impact on employment and return-to-work outcomes [60, 9]. It follows that cancer survivors are likely 
to preference interventions that are the most accessible in terms of costs and require the least amount of time 
away from work. Therefore, the findings of this study may indicate that alternative and complementary therapies 
are the most appropriate for this population. 
Limitations of the study 
The key limitation of this study that should be considered is the restriction to studies written in English, as there 
was no opportunity for translation of studies in other languages. Studies presenting valid options for CRCC 
intervention in other languages may consequently been excluded. Further, the exclusion of head and neck 
cancers was important for excluding cognitive dysfunction caused by the location of the cancer, but may have 
excluded other relevant studies of effective cognitive interventions. Finally, in meta-analyses with a small 
number, heterogeneity scores have been shown to be unreliable. Analysis with a greater number of studies in the 
future may be useful in determining more accurate heterogeneity scores. 
Overall, there is a lack of acknowledgement of CRCC as a problem within the cancer survivor community, and 
an absence of studies that highlight this as an issue. As a consequence, there is also a lack of outcome measures 
that reliably measure these aspects of cognition, causing variability in the measured results of intervention trials. 
Further research is needed to clarify the effects of CRCC and variables within these effects, such as gender and 
age differences, to allow for stronger, more reliable results.  
 
CONCLUSION 
The objective of this research was to identify and categorise the interventions that have been trialled to manage 
cancer-related cognitive change. This objective has been met through the identification of 24 randomised control 
trials that fall into three categories: cognitive training, cognitive behaviour therapy, and 
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alternative/complementary therapies. The findings of this study are particularly important in clinical decision 
making for practitioners involved in cancer care and survivorship. The results suggest that, of the current 
interventions, best practice for improving cancer-related cognitive change may be cognitive training or 
alternative therapies, such as yoga or mindfulness techniques. As the literature currently stands, cognitive 
behaviour therapy does not have strong evidence supporting its use in these populations.  
Clinicians should also be aware of the saturation of breast cancer populations in the literature, particularly within 
the American context, as this is also likely to inform decisions and impact confidence in recommending 
interventions to survivors. Caution should also be taken when recommending any cognitive intervention as a 
number of studies demonstrate high potential for selection bias. Finally, clinicians may want to consider the time 
and financial burden of the interventions they recommend to patients. In this case, results of this review suggest 
that complementary and alternative therapies should be considered first. The findings of this review provide 
evidence for the funding of services beyond medical interventions for individuals experiencing cancer-related 
cognitive change. 
For future research, the findings also suggest the need for further high-quality randomised control trials 
representing a broader spectrum of cancer survivor populations. Future research should also focus on the use of 
exercise and physical activity interventions to directly address cognitive concerns. In future, efforts should be 
made to address selection bias within research to improve the strength of the evidence.  
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Appendix IV: Intervention quality assessment criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level of training 
High- Healthcare professional trained in cog (psych, OT, etc.) 
Mod- Health professional not specific to cog (nurse, physio, etc.) 
Low- No professional cog background or training 
Intensity 
High- 5+ intervention sessions, completed at therapy site) 
Mod- 1-4 intervention sessions up to 60 minutes in duration, at-home completion (eg, online) 
Low- Brochures/education provided, nil group or individual intervention sessions 
 
 
Duration 
High- long-term intervention, 6+ weeks in duration 
Mod- short-term intervention, up to 6 weeks in duration 
Low- one-off intervention 
Last evaluation time 
High- measures assessed 2+ months post- intervention 
Mod- measures assessed up to 2 months post-intervention 
Low- measures taken immediately post-intervention only 
Cognitive measures 
High- Highly valid for cognitive assessment, combination of neurocognitive testing and subjective 
measures 
Mod- up to two measures, either objective or subjective 
Low- Tool not validated for cognition, single measure 
Accessibility of intervention 
High- Accessible to population without restriction, no prescription or training needed  
Mod- Some training needed or access to health professional (eg, physio) 
Low- minimally accessible, specific eligibility criteria, prescription from healthcare professional 
required 
